Importer of Controlled Substances Application: AndersonBrecon Inc. dba PCI of Illinois, 27248-27249 [2020-09707]

Download as PDF 27248 Federal Register / Vol. 85, No. 89 / Thursday, May 7, 2020 / Notices DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–643] Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI) ACTION: Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DEPARTMENT OF JUSTICE In accordance with 21 CFR 1301.34(a), this is notice that on April 10, 2020, Almac Clinical Services Incorp. (ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964, applied to be registered as an importer of the following basic class(es) of a controlled substance: Bulk Manufacturer of Controlled Substances Application: Alcami Wisconsin Corporation SUPPLEMENTARY INFORMATION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 8, 2020. Such persons may also file a written request for a hearing on the application on or before June 8, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette DATES: Controlled substance Drug code Schedule Noroxymorphone ...... 9668 II The company plans to import the listed controlled substance in dosage form to conduct clinical trials. William T. McDermott, Assistant Administrator. Drug Enforcement Administration [Docket No. DEA–639] ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 6, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: In accordance with 21 CFR 1301.33(a), this is notice that on March 13, 2020, Alcami Wisconsin Corporation, W130N10497 Washington Drive, Germantown, Wisconsin 53022–4448, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances: SUPPLEMENTARY INFORMATION: [FR Doc. 2020–09701 Filed 5–6–20; 8:45 am] BILLING CODE 4410–09–P Controlled substance Drug code Marihuana Extract ........................................................................................................................................................... Marihuana ........................................................................................................................................................................ Tetrahydrocannabinols .................................................................................................................................................... 5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................. Thebaine .......................................................................................................................................................................... Alfentanil .......................................................................................................................................................................... The company plans to provide bulk active pharmaceutical ingredient to support clinical trials. In reference to drug codes 7350 Marihuana extract, 7360 Marihuana, and 7370 Tetrahydrocannabinols, the company plans to manufacture these substances synthetically. No other activities for these drug codes are authorized for this registration. DEPARTMENT OF JUSTICE William T. McDermott, Assistant Administrator. DATES: [FR Doc. 2020–09702 Filed 5–6–20; 8:45 am] khammond on DSKJM1Z7X2PROD with NOTICES BILLING CODE 4410–09–P VerDate Sep<11>2014 16:45 May 06, 2020 Jkt 250001 Drug Enforcement Administration [Docket No. DEA–641] Importer of Controlled Substances Application: AndersonBrecon Inc. dba PCI of Illinois ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 8, 2020. Such persons may also file a written request for a hearing on the application on or before June 8, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 7350 7360 7370 7431 9333 9737 Schedule I I I I II II 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. In accordance with 21 CFR 1301.34(a), this is notice that on March 20, 2020, AndersonBrecon Inc. dba PCI of Illinois, 5775 Logistics Parkway, Rockford, Illinois 61109–3608, applied to be registered as an importer of the following basic class(es) of a controlled substance: SUPPLEMENTARY INFORMATION: E:\FR\FM\07MYN1.SGM 07MYN1 Federal Register / Vol. 85, No. 89 / Thursday, May 7, 2020 / Notices Controlled substance Drug code Schedule Tetrahydrocannabinols 7370 I The company plans to import the listed controlled substance for clinical trial only. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. William T. McDermott, Assistant Administrator. [FR Doc. 2020–09707 Filed 5–6–20; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employment and Training Administration Notice Requesting Public Comment on the Proposed Methodology To Distribute Outcome Payments to States for the Unemployment Insurance (UI) Reemployment Services and Eligibility Assessments (RESEA) Program in Accordance With Title III, Section 306(f)(2) of the Social Security Act (SSA) Employment and Training Administration (ETA), U.S. Department of Labor (Department). ACTION: Request for public comment. AGENCY: The Department is seeking public comment on the proposed methodology to distribute RESEA outcome payments to states each fiscal year (FY) after FY 2020 as required by Section 306(f)(2), SSA. DATES: Submit written comments to the office listed in the addresses section below on or before June 8, 2020. ADDRESSES: Questions on this notice and responsive comments related to the RESEA outcome payments allocation can be submitted to the U.S. Department of Labor, Employment and Training Administration, Office of Unemployment Insurance, 200 Constitution Avenue NW, Room S– 4524, Washington, DC 20210, Attention: Lawrence Burns, or by email at DOLETA-UI-FRN@dol.gov. FOR FURTHER INFORMATION CONTACT: Lawrence Burns, Division of Unemployment Insurance Operations, at 202 693–3141 (this is not a toll-free number), TTY 1–877–889–5627 (this is not a toll-free number), or by email at khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:45 May 06, 2020 Jkt 250001 Burns.Lawrence@dol.gov. The Department will respond to comments directly as necessary. SUPPLEMENTARY INFORMATION: ETA proposes a three-step approach to determine whether a state is eligible for RESEA Outcome Payments. The proposed approach reflects RESEA’s statutory purpose, as defined in Section 306(b)(1), SSA, to improve employment outcomes of individuals that receive unemployment compensation (UC) and to reduce the average duration of receipt of such compensation through employment. The three-step approach includes: 1. Evaluation of state reemployment performance using the RESEA program to determine if a state met or exceeded the target for the Reemployment Rate in the 2nd Quarter After Program Exit for RESEA participants performance measure; 2. Evaluation of the state’s Average UI duration to determine if the state demonstrated a decrease in its average UI duration as a result of the RESEA services provided to UI claimants; and 3. Award allocation. I. Introduction The federal-state UI program is a required partner in the comprehensive, integrated workforce system. Individuals who have lost employment through no fault of their own and have earned sufficient wage credits, may receive UI benefits if they meet initial and continuing eligibility requirements. Beginning in 2005, the Department and participating state workforce agencies have been addressing the individual reemployment needs of UI claimants and working to prevent and detect UI improper payments through the voluntary UI Reemployment and Eligibility Assessment (REA) program. Beginning in FY 2015, the voluntary RESEA program replaced the REA program. On February 9, 2018, the President signed the Bipartisan Budget Act of 2018 (Pub. L. 115–123) (BBA), which included amendments to the SSA creating a permanent authorization for the RESEA program. In FY 2019, a total of 50 states and jurisdictions operated a RESEA program. The primary goals for the RESEA program are to: Improve employment outcomes for individuals that receive UC and to reduce average duration of receipt of UC through employment; strengthen program integrity and reduce improper payments; promote alignment with the broader vision of the Workforce Innovation and Opportunity Act (WIOA)—increasing program integration and service delivery for job seekers; and establish RESEA as an entry point to PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 27249 other workforce system partner programs for individuals receiving UC. II. Background The RESEA provisions are contained in Section 30206 of the BBA, enacting Section 306 of the SSA. In addition to program requirements, Section 306 of the SSA also contains provisions for the funding of the RESEA program. The law specifies three uses and designates the proportion of annual appropriations to be assigned to these uses: (1) Base funding for states to operate the RESEA program (84 percent to 89 percent depending on the year); (2) outcome payments designed to reward states meeting or exceeding certain criteria (10 percent to 15 percent of the appropriation depending on the year); and (3) up to one percent for the Secretary of Labor to use for research and technical assistance to states. Additionally, the law requires the Department to develop a methodology to allocate and distribute base funding and outcome payments to states beginning in FY 2021. In August 2019, ETA published a Notice in the Federal Register to inform states of the methodology to allocate base funding to states for the RESEA program. Details regarding the RESEA base formula allocation methodology can be found at: https:// www.federalregister.gov/documents/ 2019/08/08/2019-16988/allocatinggrants-to-states-for-reemploymentservices-and-eligibility-assessmentsresea-in. The present Notice proposes the methodology to distribute RESEA outcome payments to states. Section 306(f)(2)(A), SSA requires ETA to make ‘‘outcome payments’’ to states that meet or exceed the outcome goals for reducing the average duration of receipt of UC by improving employment outcomes. The law specifically states: ‘‘IN GENERAL.—Of the amounts made available for grants under this section for each fiscal year after 2020, the Secretary shall reserve a percentage equal to the outcome reservation percentage 1 for such fiscal year for outcome payments to increase the amount otherwise awarded to a State under paragraph (1). Such outcome payments shall be paid to States conducting reemployment services and eligibility assessments under this section that, during the previous fiscal year, met or exceeded the outcome goals provided in subsection (b)(1) related to reducing the average duration of receipt of unemployment compensation by improving employment outcomes’’. 1 Section 306(f)(2)(B), SSA defines the ‘‘outcome reservation percentage’’ as 10 percent for fiscal years 2021 through 2026 and 15 percent for fiscal years thereafter. E:\FR\FM\07MYN1.SGM 07MYN1

Agencies

[Federal Register Volume 85, Number 89 (Thursday, May 7, 2020)]
[Notices]
[Pages 27248-27249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09707]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-641]


Importer of Controlled Substances Application: AndersonBrecon 
Inc. dba PCI of Illinois

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before June 8, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before June 8, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on March 20, 2020, AndersonBrecon Inc. dba PCI of 
Illinois, 5775 Logistics Parkway, Rockford, Illinois 61109-3608, 
applied to be registered as an importer of the following basic 
class(es) of a controlled substance:

[[Page 27249]]



------------------------------------------------------------------------
                                          Drug
         Controlled substance             code           Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols.................     7370   I
------------------------------------------------------------------------

    The company plans to import the listed controlled substance for 
clinical trial only. Approval of permit applications will occur only 
when the registrant's business activity is consistent with what is 
authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to 
the import of Food and Drug Administration-approved or non-approved 
finished dosage forms for commercial sale.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-09707 Filed 5-6-20; 8:45 am]
 BILLING CODE 4410-09-P